BRIEF—Neurogene now a publicly traded company

Today, New York-based Neurogene, a specialist in rare neurological diseases, announced the close of its merger with Neoleukin Therapeutics they announced in July, and has begun trading on the NASDAQ Global Market under the ticker “NGNE.”

Neurogene is a clinical stage genetic medicines company developing a pipeline of differentiated genetic medicines, including NGN-401 for treatment of Rett syndrome, which uses novel gene regulation technology for a potential best-in-class profile.

Rett syndrome is a debilitating, X-linked, neurodevelopmental disorder with significant unmet medical need.

There has been a surge of interest in Rett syndrome programs following the approval and launch of Acadia’s Daybue, which has significantly outperformed expectations, validating the high unmet need and strong demand in this market, as well as the early clinical data reported from Taysha.